Myelofibrosis: Difference between revisions

Jump to navigation Jump to search
Zorkun (talk | contribs)
WikiBot (talk | contribs)
m Bot: Automated text replacement (-Category:Primary care +)
 
(51 intermediate revisions by 13 users not shown)
Line 1: Line 1:
__NOTOC__
'''For patient information, click [[Myelofibrosis (patient information)|here]]'''
{{DiseaseDisorder infobox |
{{DiseaseDisorder infobox |
   Name          = Myelofibrosis |
   Name          = Myelofibrosis |
  ICD10          = {{ICD10|C|94|5|c|81}}, {{ICD10|D|47|1|d|37}} |
  ICD9          = {{ICD9|289.89}} |
   Image          = Myelofibrosis micro.jpg|
   Image          = Myelofibrosis micro.jpg|
   Caption        = Bone marrow: Myelofibrosis: High mag H&E excellent example of myelofibrosis. <br> <small> [http://www.peir.net Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology] </small> |
   Caption        = Bone marrow: Myelofibrosis: High mag HandE excellent example of myelofibrosis. <br> <small> [http://www.peir.net Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology] </small> |
  ICDO          = 9932, 9961 |
  OMIM          = |
  DiseasesDB    = 8616 |
  MedlinePlus    = |
  eMedicineSubj  = |
  eMedicineTopic = |
  MeshID          = D009191 |
}}
}}
{{Search infobox}}
{{Myelofibrosis}}
{{CMG}}
{{CMG}} {{AE}} {{Sab}}; {{MJK}}; {{SR}}


{{EH}}
{{SK}} Agnogenic myeloid metaplasia; AMM; Myeloid metaplasia; Myeloid metaplasia, NOS; Myelofibrosis with myeloid metaplasia; MMM; Assmann's disease; Chronic granulocytic-megakaryocytic myelosis; Chronic granulocytic megakaryocytic myelosis; Megakaryocytic myelosclerosis; Chronic idiopathic myelofibrosis; CIMF; Heuck-Assmann disease; Idiopathic myelofibrosis; Primary myelofibrosis; PMF; Prefibrotic primary myelofibrosis; Secondary myelofibrosis; Myelosclerosis; Osteomyelofibrosis; Osteomyelosclerosis; Myeloproliferative disorder


==Overview==
==[[Myelofibrosis overview|Overview]]==


'''Myelofibrosis with myeloid metaplasia''', also known as '''agnogenic myeloid metaplasia''', '''chronic idiopathic myelofibrosis''', and '''primary myelofibrosis''',<ref>Older terms include "myelofibrosis with myeloid metaplasia" and "agnogenic myeloid metaplasia". The [[World Health Organization]] utilizes the name "chronic idiopathic myelofibrosis", while the International Working Group on Myelofibrosis Research and Treatment calls the disease "primary myelofibrosis".</ref> was first described in 1879 and is currently classified as a [[myeloproliferative disease]] caused by the growth and proliferation of an abnormal [[bone marrow]] stem cell, resulting in the [[fibrosis|replacement of the bone marrow with fibrous connective tissue]]. An eponym for the disease is Heuck-Assmann disease, or Assmann's Disease.
==[[Myelofibrosis historical perspective|Historical Perspective]]==


==Pathophysiology==
==[[Myelofibrosis classification|Classification]]==


The bone marrow is replaced by collagen fibrosis, impairing the patient's ability to generate new blood cells resulting in a progressive [[pancytopenia]]. It is usually reactive following other [[myeloproliferative disorders]], such as [[polycythemia rubra vera]] or [[essential thrombocytosis]]. Extramedullary hematopoeisis occurs as the haemopoetic cells migrate away from the bone marrow, to the liver and spleen. Patients often have [[hepatosplenomegaly]] and [[poikilocytosis]].
==[[Myelofibrosis pathophysiology|Pathophysiology]]==


In primary myelofibrosis, a progressive scarring ([[fibrosis]]) of the bone marrow occurs. As a result, blood forms in sites other than the bone marrow, such as the [[liver]] and [[spleen]]. This causes an enlargement of these organs. The cause and risk factors are unknown.  It commonly occurs in the spent phase of [[Polycythemia rubra vera]], possibly in response to the medication [[hydroxyurea]] poisoning the marrow.
==[[Myelofibrosis causes|Causes]]==


Genetic associations with [[JAK2]]<ref name="pmid15781101">{{cite journal |author=Baxter EJ, Scott LM, Campbell PJ, ''et al'' |title=Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders |journal=Lancet |volume=365 |issue=9464 |pages=1054–61 |year=2005 |pmid=15781101 |doi=10.1016/S0140-6736(05)71142-9 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(05)71142-9}}</ref> and [[Myeloproliferative leukemia virus oncogene|MPL]]<ref name="pmid16834459">{{cite journal |author=Pikman Y, Lee BH, Mercher T, ''et al'' |title=MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia |journal=PLoS Med. |volume=3 |issue=7 |pages=e270 |year=2006 |month=July |pmid=16834459 |pmc=1502153 |doi=10.1371/journal.pmed.0030270 |url=http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030270}}</ref> have been described.
==[[Myelofibrosis differential diagnosis|Differentiating Myelofibrosis from other Diseases]]==


== Signs and symptoms == 
==[[Myelofibrosis epidemiology and demographics|Epidemiology and Demographics]]==
*Abdominal fullness related to an [[splenomegaly|enlarged spleen]] (splenomegaly).
*Bone pain
*Bruising and easy bleeding due to inadequate numbers of [[platelets]]
*Fatigue
*Increased susceptibility to infection, such as [[pneumonia]] or [[diarrhea]]
*Pallor and shortness of breath while doing physical work due to [[anemia]]


==Diagnosis==
==[[Myelofibrosis risk factors|Risk Factors]]==


Diagnosis is based upon:
==[[Myelofibrosis screening|Screening]]==


* [[Normochromic]] normocytic [[anaemia]]
==[[Myelofibrosis natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
* Red cell [[poikilocytosis]] on blood film (tear-drop shaped RBCs)
* JAK 2 mutation on Val 617 Phe locus in 50%
* Raised levels of [[lactate dehydrogenase]]
* Raised [[neutrophil alkaline phosphatase]] score
* [[Bone marrow biopsy]] may show increased cellularity and fibrosis


The patient with the myelofibrosis should be tested for [[Tuberculosis]] even if the patient doesn't manifest the symptoms of TB. There is strong evidence of myelofibrois improvement with the antituberculous treatment.
==Diagnosis==
[[Myelofibrosis diagnostic study of choice|Diagnostic Study of Choice]] | [[Myelofibrosis history and symptoms|History and Symptoms]] | [[Myelofibrosis physical examination|Physical Examination]] | [[Myelofibrosis laboratory tests|Laboratory Findings]] | [[Myelofibrosis electrocardiogram|Electrocardiogram]] | [[Myelofibrosis x ray|X Ray]] | [[Myelofibrosis CT|CT]] | [[Myelofibrosis MRI|MRI]] | [[Myelofibrosis echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Myelofibrosis other imaging findings|Other Imaging Findings]] | [[Myelofibrosis other diagnostic studies|Other Diagnostic Studies]]


==Diagnostic Findings==
==Treatment==
[[Myelofibrosis medical therapy|Medical Therapy]] | [[Myelofibrosis surgery|Surgery]] | [[Myelofibrosis primary prevention|Primary Prevention]] | [[Myelofibrosis secondary prevention|Secondary Prevention]] | [[Myelofibrosis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Myelofibrosis future or investigational therapies|Future or Investigational Therapies]]


===MRI===
==Case Studies==
[[Myelofibrosis case study one|Case # 1]]


([http://www.radswiki.net Images courtesy of RadsWiki])
<gallery>
Image:Myelofibrosis_MRI_001.jpg|Myelofibrosis
Image:Myelofibrosis_MRI_002.jpg|Myelofibrosis
</gallery>
<gallery>
Image:Myelofibrosis_MRI_003.jpg|Myelofibrosis
Image:Myelofibrosis_MRI_004.jpg|Myelofibrosis
</gallery>
== References ==
{{reflist}}
<br>
{{Hematology}}
{{Hematological malignancy histology}}
{{SIB}}


==Related chapters==
* [[Myelophthisic anemia]]


[[Category:Medicine]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Oncology]]
[[Category:Oncology]]
 
[[Category:Neurology]]
[[bn:মজ্জাকাঠিন্য]]
[[Category:Neurosurgery]]
[[de:Osteomyelofibrose]]
[[Category:Up-To-Date]]
[[fr:Splénomégalie myéloïde]]
[[it:Mielofibrosi]]
[[pl:Mielofibroza]]
 
{{WH}}
{{WS}}

Latest revision as of 06:34, 28 July 2020

For patient information, click here

Template:DiseaseDisorder infobox

Myelofibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelofibrosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelofibrosis

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelofibrosis

CDC on Myelofibrosis

Myelofibrosis in the news

Blogs on Myelofibrosis

Directions to Hospitals Treating Myelofibrosis

Risk calculators and risk factors for Myelofibrosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]; Mohamad Alkateb, MBBCh [3]; Sujit Routray, M.D. [4]

Synonyms and keywords: Agnogenic myeloid metaplasia; AMM; Myeloid metaplasia; Myeloid metaplasia, NOS; Myelofibrosis with myeloid metaplasia; MMM; Assmann's disease; Chronic granulocytic-megakaryocytic myelosis; Chronic granulocytic megakaryocytic myelosis; Megakaryocytic myelosclerosis; Chronic idiopathic myelofibrosis; CIMF; Heuck-Assmann disease; Idiopathic myelofibrosis; Primary myelofibrosis; PMF; Prefibrotic primary myelofibrosis; Secondary myelofibrosis; Myelosclerosis; Osteomyelofibrosis; Osteomyelosclerosis; Myeloproliferative disorder

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case # 1


Related chapters